G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
72 hedge funds and large institutions have $15.8M invested in G1 Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 17 closing their positions.
613% more call options, than puts
Call options by funds: $585K | Put options by funds: $82K
10% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 21
10% less funds holding
Funds holding: 80 → 72 (-8)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
59% less capital invested
Capital invested by funds: $38.6M → $15.8M (-$22.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$892K |
| 2 |
Millennium Management
New York
|
+$853K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$361K |
| 4 |
Two Sigma Advisers
New York
|
+$259K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$259K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
-$6.33M |
| 2 |
JP Morgan Chase
New York
|
-$4.08M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$477K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$422K |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$375K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCM
76
Graham Capital Management
Rowayton,
Connecticut
| – | -$139K | -55,805 | Closed |
|
77
UBS AM
Chicago,
Illinois
| – | -$106K | -39,600 | Closed |
|
78
Allspring Global Investments
Charlotte,
North Carolina
| – | -$78.3K | -31,443 | Closed |
|
|
LCM
79
Laurion Capital Management
New York
| – | -$66.4K | -26,655 | Closed |
|
|
YIH
80
Y-Intercept (HK)
Hong Kong
| – | -$56.9K | -22,855 | Closed |
|
|
SSA
81
Schonfeld Strategic Advisors
New York
| – | -$43.3K | -17,400 | Closed |
|
82
Financial Engines Advisors
Santa Clara,
California
| – | -$37.6K | -15,107 | Closed |
|
|
TSS
83
Two Sigma Securities
New York
| – | -$31.3K | -12,587 | Closed |
|
84
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$24.1K | -12,471 | Closed |
|
|
SPIA
85
Steward Partners Investment Advisory
New York
| – | -$7.47K | -3,000 | Closed |
|
86
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.42K | -735 | -89% |
|
87
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$1.69K | -678 | Closed |
|
|
IGWM
88
ICA Group Wealth Management
Denver,
Colorado
| – | -$125 | -50 | Closed |
|
GTHX Hedge Fund Activity: Q3 2023 in Review
72 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2023, worth a combined $15.8M — down 59% from $38.6M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of GTHX and 11 opened new positions — a net loss of 6 holders — while 21 trimmed existing stakes and 23 added.
The largest buyer was Marshall Wace, adding an estimated $892K. The largest seller was Fisher Asset Management, exiting entirely with an estimated $6.33M sold.
- 72 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2023, down from 80 in Q2 2023.
- Funds reported $15.8M of G1 Therapeutics, Inc. Common Stock stock for Q3 2023, down 59% quarter-over-quarter.
- 11 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2023 and 17 closed out, a net change of -6 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q3 2023 was Marshall Wace, an estimated $892K added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2023 was Fisher Asset Management, an estimated $6.33M sold.
Based on aggregated 13F filings for Q3 2023.